Protalix BioTherapeutics (PLX) Assets Average (2011 - 2026)

Protalix BioTherapeutics has reported Assets Average for 15 years, with the latest figure at $92.3 million in Q1 2026.

• For the quarter ending Q1 2026, Assets Average rose 25.37% year-over-year to $92.3 million; the trailing twelve-month figure through Mar 2026 stood at $92.3 million (up 25.37% YoY), and the FY2025 full-year result was $77.9 million, down 1.32% from the prior year.
• Assets Average for Q1 2026 stood at $92.3 million, up from $82.3 million in the prior quarter.
• The five-year high for Assets Average was $92.3 million in Q1 2026, with the low at $56.2 million in Q4 2022.
• Average Assets Average over 5 years is $75.9 million, with a median of $76.6 million recorded in 2024.
• Year-over-year, Assets Average slumped 38.85% in 2022 and jumped 52.9% in 2023.
• Tracing PLX's Assets Average over 5 years: stood at $56.2 million in 2022, then jumped by 52.9% to $86.0 million in 2023, then declined by 21.52% to $67.5 million in 2024, then climbed by 21.95% to $82.3 million in 2025, then advanced by 12.19% to $92.3 million in 2026.
• The last three Assets Average figures came in at $92.3 million (Q1 2026), $82.3 million (Q4 2025), and $80.4 million (Q3 2025), per Business Quant data.

Peer Comparison